Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Clinical trial NCT03976375 · COMPLETED
Trial details
- NCT number
- NCT03976375
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-26
- Primary completion
- 2023-08-11
- Enrollment
- 422
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.